A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: Protocol for the immunosuppressant regimens for Living FEtuses (ILIFE) Trial

Shaoying Yang
Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine
https://orcid.org/0000-0001-9091-4209

Ruoning Ni
Department of Internal Medicine, Saint Agnes Hospital, Baltimore

Yikang Lu
Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Suli Wang
Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Feng Xie
Department of Health Research Methods, Evidence and Impact (formerly Clinical Epidemiology and Biostatistics), McMaster University

Chunyan Zhang
Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Liangjing Lu (✉ lu_liangjing@163.com)
https://orcid.org/0000-0001-9116-6038

Study protocol

Keywords: Prednisone, Hydroxychloroquine, Recurrent pregnancy loss, Recurrent spontaneous abortion, Undifferentiated connective tissue disease, Randomised controlled trial

DOI: https://doi.org/10.21203/rs.2.13361/v4

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Undifferentiated connective tissue disease (UCTD) is known to induce adverse pregnancy outcomes, and even recurrent spontaneous abortion (RSA) by placental vascular damage and inflammation activation. Anticoagulation can prevent pregnancy morbidities. However, it is unknown whether the addition of immune suppressant to anticoagulation can prevent spontaneous pregnancy loss in UCTD patients. The purpose of this study is to evaluate the efficacy of hydroxychloroquine (HCQ) and low-dose prednisone on recurrent pregnancy loss for women with UCTD.

Methods: The Immunosuppressant for Living Fetuses (ILIFE) Trial is a three-arm, multicenter, open-label randomized controlled trial with the primary objective of comparing hydroxychloroquine combined with low-dose prednisone and anticoagulation with anticoagulation alone in treating UCTD women with recurrent spontaneous abortion. The third arm of using hydroxychloroquine combined with anticoagulant for secondary comparison. A total of 426 eligible patients will be randomly assigned to each of the three arms with a 1:1:1 allocation ratio. The primary outcome is the rate of live births. Secondary outcomes include adverse pregnancy outcomes and progression of UCTD.

Discussion: This is the first multi-center, open-label, randomized controlled trial which evaluates the efficacy of immunosuppressant regimens on pregnancy outcomes and UCTD progression. It will provide evidence on whether the immunosuppressant ameliorates the pregnancy prognosis in UCTD patients with RSA and the progression into defined connective tissue disease.

Trial registration: ClinicalTrials.gov, NCT03671174. Registered on 14 September 2018.
https://www.clinicaltrials.gov/ct2/show/NCT03671174

Background

Undifferentiated connective tissue disease (UCTD) is defined as at least one symptom or sign suggesting connective tissue diseases (CTDs) and with presence of at least one of auto-antibodies, while not fulfilling any classification criteria of a defined CTD[1,2]. UCTD accounts for 20%-52% of patients with CTDs and is characterized by varying symptom onset time and antibody profiles. UCTD is more common in women, with a male-to-female ratio ranging from 1:15 to 1:17, predominantly at the reproductive age with a prevalence of 2.5% in pregnant women[2-5]. UCTD may evolve into definite CTDs like systemic lupus erythematosus (SLE), systemic sclerosis, primary Sjögren’s syndrome, mixed connective tissue disease, systemic vasculitis, polymyositis and rheumatoid arthritis[6].

UCTD is the most common rheumatic disease diagnosed during the first trimester of pregnancy and plays a potential causal role of autoimmune disorders in the occurrence of pregnancy complications[7]. Antinuclear antibodies and inflammation in UCTD may impair platelet activity, unbalance coagulation/anticoagulation, increase the risk of thrombosis, cause collagen synthesis defect and endothelial dysfunction[8-10]. Therefore, it could increase uterine artery resistance, inhibit placenta development and remodelling, and thus increase the risk of pre-eclampsia, intrauterine growth retardation.
(IUGR), small for gestational age infant (SGA) and recurrent spontaneous abortion (RSA)[3,11-14]. A multicentre retrospective cohort study showed that 21% of pregnancy resulted in miscarriages or stillbirths[15]. Spinillo found that women with UCTD had a higher rate (39.0%) of at least 1 spontaneous pregnancy loss than healthy controls with an odds ratio of 5.92 (95% CI, 2.1-17.8)[14]. Other studies reported that the prevalence of adverse pregnancy outcomes ranged from 27% to 30% in women with UCTD[13,16].

In addition to adverse pregnancy outcomes, women with UCTD may experience a disease flare and even evolve into definite CTDs during the course of pregnancy and puerperium[17,18]. The incidence of disease flare was about 24%~32%, higher than the 11% in the non-pregnant patients[13,16]. An average of 30% of UCTD women eventually develop a well-defined CTD[18-21], especially during pregnancy, and require treatments with steroids and immunosuppressant like hydroxychloroquine (HCQ).

There is no consensus or guideline about treatments for recurrent spontaneous abortion (RSA) in pregnant women with UCTD. UCTD shares similar pathogenesis of placental vascular thrombosis as systemic lupus erythematosus +/- antiphospholipid antibody syndrome (APS) for which low-dose aspirin and low-molecular-weight heparin (LMWH) are used to prevent fetal losses and improve pregnancy outcomes[22,23]. Therefore, antiaggregation and anticoagulation was considered as a safe way reducing the risk of miscarriages among women with UCTD [24,25]. Despite low-dose aspirin and LMWH treatments, women suffered from RSA with UCTD still suffered from pregnancy morbidity[24,26].

Taking placental inflammation and imbalance of immune system of UCTD into consideration, immunosuppression is hypothesized to be a potential rescue. Immunosuppression may also be beneficial in reducing disease recurrence and progression. Currently, commonly used immunosuppressant includes low-dose corticosteroids, HCQ, azathioprine, cyclosporin, immunoglobulin[3]. In guideline on prescribing drugs in pregnancy and breastfeeding, corticosteroids and HCQ is compatible with each trimester of pregnancy [level of evidence 1++, grade of recommendation A, strength of agreement 100%], and HCQ should be continued during pregnancy in women planning a pregnancy with rheumatic disease in need of treatment[27]. Corticosteroids and HCQ used in nearly half of UCTD patients and considered as symptomatic treatment during non-pregnancy period. But the treatment effect on pregnant women with UCTD was poorly studied and barely acknowledged and most studies are small-scale observational studies. The studies of treatment in recurrent miscarriage, SLE and APS showed that prednisone and HCQ could reduce the incidence of disease flares and obstetric complications. Low dose of corticosteroids were proved to inhibit T cells and Natural Killer (NK) cells, to improve the fertilization rate[28,29], and to decelerate the progression into rheumatic diseases. Several studies showed that prednisolone of 5-20mg per day can improve pregnancy outcomes[26,30-33]. However, there still lacks a large clinical trial to identify an optimal treatment. It was observed that HCQ was associated with delayed SLE onset in CTD [34], decrease the risk of disease flare in pregnant SLE patients[35-37], increase the live birth rate, and reduce preterm delivery in antiphospholipid antibodies (aPL) positive patients[38], and prevent congenital heart block in neonates exposed to anti-SSA and anti-SSB antibodies[39]. It remains unknown whether HCQ could affect pregnancy outcomes of UCTD women. A study of 133 pregnancies of CTDs showed
evidence for the safety of HCQ therapy during pregnancy but no differences in live birth rate [40]. A systemic review showed that HCQ does not appear to be associated with any increased risk of congenital defects, spontaneous abortions, fetal death, prematurity or decreased numbers of live births in patients with autoimmune diseases[41]. Recently data from 66 UCTD patients with RSA treated by hydroxychloroquine plus low-dose prednisone combined with anticoagulation in our center seemed promising. There were 66 successful pregnancies (the live birth rate 97.1%) and only 5 obstetric complications in 68 pregnancies. The impact on pregnancy outcome of UCTD is probably less severe than well-established rheumatic diseases, however, UCTD needs to be paid more attention to because of its high prevalence.

Given that RSA in UCTD patients is mediated by autoimmune factors and may be improved by the addition of immune suppressant to anticoagulation. The objective of the ILIFE trial is to assess efficacy of low-dose corticosteroids and HCQ combined with anticoagulation in treating UCTD patients with recurrent pregnancy loss.

**Methods/design**

**Study design**

The ILIFE trial is a three-arm, multicenter, open-label, randomized controlled trial (RCT) to assess efficacy of low-dose corticosteroids and HCQ combined with anticoagulation in treating UCTD women with recurrent pregnancy loss.

Patients will be enrolled at rheumatology outpatient clinics in six university-affiliated, tertiary hospitals in China, including Shanghai Renji Hospital, the First Affiliated Hospital of Anhui Medical University, China-Japan Union Hospital of Jilin University, the Affiliated Wuxi No.2 People’s Hospital of Nanjing Medical University, Jiangsu Province Hospital and Xiangya Hospital of Central South University. The study design is presented in the flowchart in Fig. 1. Standard protocol items: recommendations for interventional trials (SPIRIT) are provided as an additional file 1. This study was approved by institutional review boards (IRB) of study sites.

**Recruitment**

The study population consists of UCTD women who had experienced at least two miscarriages and try to conceive. Rheumatologists in each study site will check inclusion and exclusion criteria of UCTD women. A research assistant will present the study information during recruitment. Eligible patients who provide informed consents will be enrolled to the trial.

The anticipated duration of recruitment is 2 years, and the duration of participation of each patient is about 2 years.

**Inclusion criteria**
Women who meet the following inclusion criteria will be eligible to participate in the study:

- At reproductive age (20-40 years old).
- Trying to conceive.
- Diagnosed with UCTD[2]: at least one symptoms or signs suggesting CTD and with at least one presence of auto-antibodies, including antinuclear antibody (ANA), anti-extractable nuclear antigen (ENA) antibodies, anti-double-stranded DNA (ds-DNA) antibody, aPL, anti-cyclic citrullinated peptide (CCP) antibody, while not fulfilling any classification criteria of a defined CTD.
- Diagnosed with RSA[42]: two or more failed pregnancies of unknown origin in all trimesters.
- Providing written informed consent.

**Exclusion criteria**

Women who meet any of the following criteria will be excluded from the study:

- Any known etiology of previous pregnancy loss:
  1. Diagnosis of antiphospholipid antibody syndrome.
  2. Known paternal, maternal or embryo chromosome abnormality.
  3. Maternal endocrine dysfunction: corpus luteal insufficiency; polycystic ovarian syndrome; premature ovarian failure (follicle stimulating hormone, FSH $\geq$ 20uU/L in follicular phase); hyperprolactinemia; thyroid disease; diabetes mellitus; other hypothalamic–pituitary–adrenal axis abnormality.
  4. Maternal anatomical abnormality: uterine malformation (using Thessaloniki ESHRE / ESGE consensus criteria, gynecological examination, ultrasound results and opinions of obstetricians and gynecologists); Asherman syndrome; cervical incompetence; uterine fibrosis more than 5 cm (including submucosal and/or intramural).
  5. Vaginal infection.

- Any known severe cardiac, hepatic, renal, hematological or endocrinal diseases:
  1. Alanine transaminase (ALT) or aspartate transaminase (AST) more than twice the upper limit of normal.
  2. Clearance of creatinine less than 30mL/min.
  3. Leucocytes less than $2.5 \times 10^9/L$, or Hemoglobine less than 85g/L, or Platelet less than $50 \times 10^9/L$.

- Any active infection:
  1. Active viral hepatitis including hepatitis B virus (HBV), hepatitis C virus (HCV).
  2. Active infection including Varicella-zoster virus (VZV), human immunodeficiency virus (HIV), syphilis or tuberculosis.
• Allergic to prednisone, hydroxychloroquine, LMWH or aspirin.

• Disease history as follows:

1. Past history of digestive ulcers or upper gastrointestinal hemorrhage.
2. Past history of malignancy.
3. Past history of epilepsy or psychotic disorders.

• Women using assisted conception.
• Woman unable to consent.

**Randomization and blinding**

The primary objective of this trial is to investigate the superiority of low-dose corticosteroids and HCQ combined with anticoagulation compared with anti-coagulant only in UCTD women with RSA. A third arm of using hydroxychloroquine combined with anticoagulant for a secondary comparison only. It’s an open-label trial but data analysts will be blinded. After obtaining the written informed consent, eligible patients will be randomized to one of the three treatment arms with a ratio of 1:1:1 stratified by site. Randomized numbers will be generated through SAS software at the trial methods centre located in Shanghai Renji Hospital. A special designed sealed opaque two-couplet random allocation envelope will be used for the randomization and allocation. The first couplet is to collect the enroll information and the second couplet is to show the allocation information. The content of the first couplet can be completely copied to the second couplet. Each time a new patient is enrolled in the study, a new envelope will be opened in order. Once the envelope is opened, it can’t be resealed.

**Treatments**

Included patients are randomized to three treatment groups: 1) low-dose prednisone (10mg once daily orally), HCQ (the maximal tolerance dose ranges from 100mg to 400mg daily orally), and anticoagulants using low-dose aspirin (50mg once daily orally) and subcutaneously administered LMWH once daily with preventive dose (enoxaparin 40mg or dalteparin 5000IU or nadroparin calcium 4100U); 2) HCQ (the maximal tolerance dose ranges from 100mg to 400mg daily orally), and the same anticoagulant treatments as in the first group; and 3) the anticoagulant treatments only. Treatments are initiated before conception (recommended 3-6 months) and stopped at 6 weeks’ post-gestation or miscarriage or after 1 year of treatment in the absence of pregnancy. Supplements such as folic acid, calcium tablet and vitamins are allowed throughout pregnancy.

**Assessments and data collection**

The assessments will be conducted at the screening and preparation phases and then routinely throughout the trial. The screening phase will last for 4 weeks. General profiles including age, height, weight, ethnicity, occupation, obstetric and rheumatology histories, medication uses, allergy and antecedents will be recorded during the screening phase. Following the screening phase is the 1 year pre-
conception phase. If participants are not pregnant within 1 year, the treatment and their participation will be terminated. Once pregnancy is confirmed, the pregnancy assessments will start and the index time is set to week 0. Pregnant women will be followed once every 4 weeks in the next 42 weeks gestation period. The last visit will be conducted at 6 weeks after delivery. The assessment will be terminated when spontaneous pregnancy loss or childbirth takes place. Children's observations will last for one year after the end of the study, including vision, hearing and growth parameters. The schedules for assessments and data collection are showed in Fig. 2. Data will be collected in paper case report forms (CRFs) stored at a secure place and double entered into the electronic trial database.

Outcome measures

**Primary outcome**

The primary outcome is the rate of live births after at least 26 completed weeks of gestation.

**Secondary outcomes**

The secondary outcomes include adverse pregnancy outcomes and progression of UCTDs:

- The rate of conception. The rate of miscarriage (before 24 weeks).
- The rate of stillbirth (intrauterine death at ≥ 24 weeks).
- Premature birth (live birth between 28 and 37 weeks of gestations).
- Concerning the child: intrauterine growth retardation, gestational age and weight at birth, survival at 28 days, safety data at 42 days of life and congenital abnormality (congenital heart conduction block, neonatal lupus or malformation).
- Concerning the mother: eclampsia (new-onset hypertension after 20 weeks of gestation, with or without proteinuria more than 300mg/24h, obstetric bleeding (antepartum haemorrhage, postpartum haemorrhage), and placental abnormalities (placenta praevia), with or without any organ damage with seizures), infection(infections of upper and lower respiratory tract, gestational source, urinary tract and skin), gestational diabetes mellitus (diabetes diagnosed in the second or third trimester of pregnancy).
- Concerning the UCTD: activity of UCTD (the presence of new clinical symptoms like arthritis, rash, Reynolds phenomenon, proteinuria with or without serological activity, which requires a new treatment or an increase of current dose or even hospitalization due to disease activity), progression of UCTD ( evolution to SLE, APS, Sjogren's syndrome, systemic sclerosis and other defined CTD diagnosed by classification criteria of American College of Rheumatology).

Sample size

There is very limited evidence on the spontaneous pregnancy loss in pregnancies of women with UCTD and the reported risk rates for RSA varied substantially across studies. The live-birth rate of a randomized trial enrolling 364 women with a history of unexplained recurrent miscarriage was 69.1% in the group
receiving aspirin plus nadroparin[43]. In another cohort study of women with positive aPL, HCQ can improve the live birth rate from 57% to 67%[38]. A double-blind placebo randomized control trial involving 160 patients with unexplained recurrent miscarriage showed that the addition of prednisolone to heparin and aspirin might be beneficial, with 70.3% of women in the prednisolone group having successful pregnancy outcome versus 9.2% in the placebo group[30]. Data from 68 pregnancies in our department showed that the live birth rate was 97.1% in UCTD women with RSA treated by hydroxychloroquine plus low-dose prednisone combined with anticoagulation.

Our primary comparison is between the combined use of prednisone, HCQ and anticoagulant with the anticoagulant only. Based on our pilot and limited published data, we hypothesize that the proportion of live birth rates with the treatment strategy using prednisone, HCQ, aspirin and LMWH is 85% vs 70% for anticoagulant only. We need to enroll 363 women (121 in each group and for the third arm as well) to allow us to detect the difference in spontaneous pregnancy loss between the treatment groups with a power of 0.8 at a two-sided P value of 0.05. Since not all women would get pregnant during the trial, we planned to include about 426 participants (142 in each group) on the assumption of 90% of pregnant rate within 1 year and 5% loss to follow-up[44].

Data analysis

Our primary comparison is between the combined use of prednisone, HCQ and anticoagulant with the anticoagulant only. All data will be analyzed according to the intention-to-treat approach in which all randomized patients are included and supplemented by per-protocol analysis. A secondary comparison will be made between hydroxychloroquine combined with low-dose prednisone and anticoagulation and hydroxychloroquine combined with anticoagulant. A sensitivity analysis using multiple imputation will assess the robustness of the results to variation in the missing data assumptions. Subgroup analysis will be conducted according to the number of previous miscarriages (2, or ≥3). For categorical data, frequencies and percentages will be presented. Continuous data will be presented as the mean and standard deviation or median and interquartile range. The primary outcome will be summarized as the proportion of live birth in each group. Occurrences of the primary and secondary endpoints are compared between the treatment groups. Results are presented as risk ratios with corresponding 95% confidence intervals. A two-tailed P < 0.05 is considered statistically significant.

Trial management

A steering committee comprised of local principal investigator at each participating hospital will manage the trial. Screening and recruitment will be reviewed regularly at steering committee meetings; protocol deviations (e.g. late administration) will be distinguished from protocol violations (e.g., missed doses). Enrollment or adherence barriers will be addressed by implementing improvement strategies. Relevant clinical and laboratory data submitted to the steering committee will be checked for the completeness and accuracy. All investigators will undertake a standardized training for study procedures, data collection and adverse event reporting. The plans to promote participant retention and complete follow-up include: giving specific follow-up schedule and obtaining at least two phone contacts to ensure
communication. The research assistant will contact participants by telephone regularly to improve adherence to medication and assessments. We will record and analyze reasons for nonadherence or nonretention in the study. To maintain confidentiality, CRFs and other records will be identified by a coded number and initials only. Data tools and instruments are stored securely and access restricted to authorized study team members.

Safety monitoring

An independent data and safety monitoring board (DSMB) will meet regularly to ensure patient safety and data quality. Interim analyses of principal safety and effectiveness outcomes will be performed on behalf of DSMB by the trial statistician who are blind to the treatment assignments. Vital signs, which include blood pressure, heart rate, temperature and respiration rate, adverse events will be monitored regularly throughout the trial. Safety monitoring and surveillance will be collected, processed, reviewed, evaluated, reported and discussed, including clinical pregnancy outcomes, identified risks of drugs (additional file 2), laboratory abnormalities and imaging changes. If serious adverse outcomes or rare possible risks occur, a multidisciplinary Safety Management Team (SMT) will be established in each participating hospital and the results will be communicated with DSMB. After assessing severity and causality, rheumatologists are responsible for adjusting further treatment plan accordingly and adverse events will be communicated with DSMB as soon as possible.

Dissemination

The research team will make the data and the full study protocol available to the public. The findings of the study will be disseminated in academic journals and conference presentations.

Discussion

UCTD is the most common systemic rheumatic disorder occurred mainly in women at the reproductive age and associated with a higher rate of recurrent spontaneous abortion[14]. To date, there has not yet been an optimal therapy for treating RSA of UCTD patients. Among all the possible causes of RSA in UCTD patients, immunological dysfunction is one of reversible backgrounds affecting pregnancy outcomes. It is recommended that pregnancy in patients with SLE or APS be treated using immunotherapy and the anticoagulation therapy. It is known that the immune system imbalance and impaired vascular function in UCTD could contribute to the pathogenesis of preeclampsia and placental vascular thrombosis as is the case in SLE or APS[9,45]. Therefore, immunotherapy may play a role in reducing the immune system dysfunction and vascular injury caused by UCTD, and then decreasing the adverse pregnancy outcomes. Meanwhile, immunosuppressant may prevent patients from disease recurrence and progression into defined connective tissue disease.

The treatment experiences of pregnant women mostly came from the treatment of recurrent miscarriage, SLE and APS. The studies of treatment effect on UCTD pregnant women were with small scale instead of randomized controlled study. Based on limited published data, immunotherapy such as low dose
corticosteroids and HCQ showed clinical benefit for RSA in patients with UCTD. There still lacks a large scale, well-designed clinical trial to assess the efficacy of immunotherapy in patients with RSA and UCTD. The ILIFE study is the first RCT to evaluate the efficacy of prednisone and HCQ in this patient population. This trial focuses on ameliorating the pregnancy outcomes, investigating the role of rheumatic diseases in pregnancy, and also exploring how pregnancy modifies the progress of UCTD. We expect that the ILIFE study will provide high quality evidence to inform treatment decision making for UCTD women with RSA.

**Trial status**

Patient recruitment will begin from August 2019 to August 2021. The trial will be completed by August 2023.

Protocol date and version: June 10, 2019; version 1.1.

**Abbreviations**

ALT: Aspartate transaminase; ANA: Antinuclear antibody; aPL: Antiphospholipid antibodies; APS: Antiphospholipid antibody syndrome; AST: Alanine transaminase; CCP: cyclic citrullinated peptide; CRFs: Case report forms; CTDs: Connective tissue diseases; ds-DNA: double-stranded DNA; DSMB: Data and safety monitoring board; ENA: extractable nuclear antigen; FSH: Follicle stimulating hormone; HBV: Hepatitis B virus; HCQ: Hydroxychloroquine; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; ILIFE: the Immunosuppressant for LIving FEtuses; IRB: Institutional review boards; IUGR: intrauterine growth retardation; LMWH: Low-molecular-weight heparin; NK: Natural Killer; RSA: Recurrent spontaneous abortion; RCT: Randomized controlled trial; SGA: small for gestational age infant; SLE: Systemic lupus erythematosus; SMT: Safety Management Team; SPIRIT: Standard Protocol Items: Recommendations for Intervventional Trials; UCTD: Connective tissue diseases; VZV: V aricella-zostervirus.

**Declarations**

**Acknowledgements**

The ILIFE team appreciates the support of study coordinators at each center. We would like to thank all the staffs of six hospitals for their support of this study.

**Funding**

This work is financed by the National Key Research and Development Program of China (2017YFC0909000) grant.

**Availability of data and material**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

LLJ is the principal investigator. ZCY designed the study. YSY and NRN developed this study protocol and were also responsible for receiving ethics approval. NYN drafted the manuscript and the manuscript was revised by YSY. XF designed statistical elements of the trial. All authors are actively involved in carrying out the trial. ZCY will serve as study coordinator. YSY, WSL and LYK will participate in data collection. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Central ethical approval has been confirmed from the Institutional Review Board (IRB) of Shanghai Renji Hospital (ref approval no. KY-2019-056) and we will not begin recruiting at other centres in the trial until local ethical approval has been obtained. Any protocol amendments will require IRB approval. The protocol identification number on ClinicalTrials.gov is NCT03671174. We will conduct the study following the declaration of Helsinki and obtain informed consent from each participating patient before randomization. Study participation is voluntary and can be withdrawn at any time without provision of reason. On the consent form, participants will be asked if they agree to use of their data. Participants will be asked for permission for the research team to share relevant data with authorized study team members. Participants will also be asked for permission for collecting blood samples for storage in pre-conception period, gestational week 12 and 6 weeks after delivery.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

2 Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD, USA.

3 Department of Health Research Methods, Evidence and Impact (formerly Clinical Epidemiology and Biostatistics), McMaster University, Hamilton, Ontario, Canada.

4 Centre for Health Economics and Policy Analysis, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
References

1. Antunes M, Scirè CA, Talarico R, Alexander T, Avcin T, Belocchi C, et al. Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. RMD Open. 2019;4(Suppl 1):e786.

2. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 1999;17(5):615-20.

3. Vaz CC, Couto M, Medeiros D, Miranda L, Costa J, Nero P, et al. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol. 2009;28(8):915-21.

4. Guerrero LF, Rueda JC, Arciniegas R, Rueda JM. Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year. Rheumatol Int. 2013;33(4):1085-8.

5. Spinillo A, Beneventi F, Ramoni V, Caporali R, Locatelli E, Simonetta M, et al. Prevalence and significance of previously undiagnosed rheumatic diseases in pregnancy. Ann Rheum Dis. 2012;71(6):918-23.

6. Mosca M, Tani C, Neri C, Baldini C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev. 2006;6(1):1-4.

7. Spinillo A, Beneventi F, Locatelli E, Ramoni V, Caporali R, Alpini C, et al. The impact of unrecognized autoimmune rheumatic diseases on the incidence of preeclampsia and fetal growth restriction: a longitudinal cohort study. Bmc Pregnancy Childb. 2016;16(1):313.

8. Pandey MK, Rani R, Agrawal S. An update in recurrent spontaneous abortion. Arch Gynecol Obstet. 2005;272(2):95-108.

9. Laczik R, Soltesz P, Szodoray P, Szekanecz Z, Kerekes G, Paragh G, et al. Impaired endothelial function in patients with undifferentiated connective tissue disease: a follow-up study. Rheumatology. 2014;53(11):2035-43.

10. Spinillo A, Beneventi F, Caporali R, Ramoni V, Montecucco C. Undifferentiated connective tissue diseases and adverse pregnancy outcomes. An undervalued association? Am J Reprod Immunol. 2017;78(6):e12762.

11. Dubova EA, Klimantsev IV, Pavlov KA, Kulikova GV, Kan NE, Shchyogolev Al, et al. The expression of matrix metalloproteinases in placental tissue depends on the severity of undifferentiated connective tissue dysplasia. Bull Exp Biol Med. 2013;156(1):110-3.

12. Beneventi F, Locatelli E, Ramoni V, Caporali R, Montecucco CM, Simonetta M, et al. Uterine artery Doppler velocimetry and obstetric outcomes in connective tissue diseases diagnosed during the first trimester of pregnancy. Prenatal Diag. 2012;32(11):1094-101.

13. Mosca M, Neri R, Strigini F, Carmignani A, Totti D, Tavoni A, et al. Pregnancy outcome in patients with undifferentiated connective tissue disease: a preliminary study on 25 pregnancies. Lupus. 2002;11(5):304-7.
14. Spinillo A, Beneventi F, Epis OM, Montanari L, Mammoliti D, Ramoni V, et al. The effect of newly diagnosed undifferentiated connective tissue disease on pregnancy outcome. Am J Obstet Gynecol. 2008;199(6):631-2.

15. Radin M, Schreiber K, Cecchi I, Bortoluzzi A, Crisafulli F, de Freitas CM, et al. A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution. Rheumatology. 2020;0:1-7.

16. Castellino G, Capucci R, Bernardi S, Padovan M, Giacuzzo S, Pivato E, et al. Pregnancy in patients with undifferentiated connective tissue disease: a prospective case-control study. Lupus. 2011;20(12):1305-11.

17. Peppmueller PH. Undifferentiated Connective Tissue Disease, Mixed Connective Tissue Disease, and Overlap Syndromes in Rheumatology. Mo Med. 2016;113(2):136-40.

18. Mosca M, Tani C, Carli L, Bombardieri S. Undifferentiated CTD: A wide spectrum of autoimmune diseases. Best Pract Res Clin Rheumatol. 2012;26(1):73-7.

19. Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003;21(3):313-20.

20. Mosca M, Tani C, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Pract Res Clin Rheumatol. 2007;21(6):1011-23.

21. Cavazzana I, Franceschini F, Belfiore N, Quinzanini M, Caporali R, Calzavara-Pinton P, et al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients. Clin Exp Rheumatol. 2001;19(4):403-9.

22. Mekinian A, Costedoat-Chalumeau N, Masseau A, Tincani A, De Caroli S, Alijotas-Reig J, et al. Obstetrical APS: Is there a place for hydroxychloroquine to improve the pregnancy outcome? Autoimmun Rev. 2015;14(1):23-9.

23. Kano T, Shimizu M, Kanda T. Differences in Individual Efficacy of Two Sairei-to Preparations (Sojyutu-Sairei-to and Byakujyutu-Sairei-to) on Recurrent Spontaneous Abortions of Autoimmune Etiologies Evaluated by Antinuclear Antibody and Anticardiolipin Antibody Titers. Am J Chin Med. 2010;38(1):27-36.

24. Badawy AM, Khiary M, Sherif LS, Hassan M, Ragab A, Abdelall I. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol. 2008;28(3):280-4.

25. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol. 2009;36(2):279-87.

26. Tempfer CB, Kurz C, Bentz E, Unfried G, Walch K, Czizek U, et al. A combination treatment of prednisone, aspirin, folate, and progesterone in women with idiopathic recurrent miscarriage: a matched-pair study. Fertil Steril. 2006;86(1):145-8.
27. Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology. 2016;55(9):1693-7.

28. Tang AW, Alfrevic Z, Turner MA, Drury JA, Small R, Quenby S. A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant. Hum Reprod. 2013;28(7):1743-52.

29. Bansal AS. Joining the immunological dots in recurrent miscarriage. Am J Reprod Immunol. 2010;64(5):307-15.

30. Gomaa MF, Elkholy AG, El-Said MM, Abdel-Salam NE. Combined oral prednisolone and heparin versus heparin: the effect on peripheral NK cells and clinical outcome in patients with unexplained recurrent miscarriage. A double-blind placebo randomized controlled trial. Arch Gynecol Obstet. 2014;290(4):757-62.

31. Bramham K, Thomas M, Nelson-Piercy C, Khamashta M, Hunt BJ. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood. 2011;117(25):6948-51.

32. Kemp MW, Newnham JP, Challis JG, Jobe AH, Stock SJ. The clinical use of corticosteroids in pregnancy. Hum Reprod Update. 2015;22(2):240-59.

33. Fawzy M, Shokeir T, El-Tatongy M, Warda O, El-Refaiy AA, Mosbah A. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet. 2008;278(1):33-8.

34. James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2016;16(6):401-9.

35. Clowse MEB, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640-7.

36. Koh JH, Ko HS, Kwok S, Ju JH, Park S. Hydroxychloroquine and pregnancy on lupus ares in Korean patients with systemic lupus erythematosus. Lupus. 2014;23(6):401-7.

37. Luo Y, Zhang L, Fei Y, Li Y, Hao D, Liu Y, et al. Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years—a retrospective cohort study. Clin Rheumatol. 2015;34(10):1721-8.

38. Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2016;214(2):271-3.

39. Izmirly PM, Kim MY, Llanos C, Le PU, Guerra MM, Askanase AD, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis. 2010;69(10):1827-30.

40. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DLT, Sebbough D, Wechsler B, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred
thirty-three cases compared with a control group. Arthritis Rheum. 2003;48(11):3207-11.

41. Abarientos C, Sperber K, Shapiro DL, Aronow WS, Chao CP, Ash JY. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Saf. 2011;10(5):705-14.

42. Practice Committee of American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril. 2013;99(1):63.

43. Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyak K, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362(17):1586-96.

44. Wong LF, Schliep KC, Silver RM, Mumford SL, Perkins NJ, Ye A, et al. The effect of a very short interpregnancy interval and pregnancy outcomes following a previous pregnancy loss. Am J Obstet Gynecol. 2015;212(3):371-5.

45. de Groot CJM, van der Mast BJ, Visser W, De Kuiper P, Weimar W, Van Besouw NM. Preeclampsia is associated with increased cytotoxic T-cell capacity to paternal antigens. Am J Obstet Gynecol. 2010;203(5):491-6.

Figures
Figure 1

Trial Design Schema
Figure 2

SPIRIT figure\: Time schedule of enrollment, interventions, and assessments.* Blood count, Biochemistry, Autoimmune profile, Coagulation profile, et al.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SPIRIT2013Checklist.pdf
- Additionalfile2.Adverseeventsofmedications.docx